The new Dogma meets Thomas Kuhn’s definition of a paradigm shift. The DNA/RNA Dogma is sufficiently unprecedented to attract ...

Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

According to Coherent Market Insights, the global plasmid DNA manufacturing market size is estimated to be valued at USD 735.67 million in 2022 and is expected to surpass USD 3,733.50 million by 2030, ...

【ITBEAR】日本知名COSER plasmid_cos近日推出了最新力作，以《原神》中的人气角色久岐忍为主题，引发了广泛关注。这次的作品不仅将角色形象还原得淋漓尽致，更凸显了plasmid_cos的卓越身材与出色的演绎能力。

Thanks to technological advancements in nucleic acid sequencing and the shift toward molecular research and personalized medicine, omics approaches have become increasingly important in studying the ...

at 07:05 Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global ...

iGEM Toronto competed at the International Genetically Engineered Machine competition in Paris, France in October ...

A new study finds that two subtypes of pathogenic Escherichia coli (E. coli) produce five to 16 times more protective capsular “slime” when Enterococcus faecalis (EF) is present. The finding could ...